_cathie-wood39s-ark-invest39s-third-largest-holding-is-this-little-known-biotech-company-harnessing-ai-for-drug-treatment.jpg "Cathie Wood's ARK Invest's Third-Largest Holding Is this Little Known Biotech Company Harnessing AI for Drug Treatments from eva case revolution controller Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 0:40
👁 View: 710K times
✓ Published: 14-May-2024
👁 View: 710K times
✓ Published: 14-May-2024
Description:
Cathie Wood's ARK Invest has been buying shares of Recursion Pharmaceuticals, a biotech company using AI to speed up drug discovery. It is now the third-largest holding in her ARK Genomic Revolution ETF. Recursion has developed an AI-powered operating system that conducts up to 2.2 million weekly experiments to test drug candidates in an automated laboratory, advancing only the most promising compounds to clinical trials. Using AI this way could allow Recursion to launch drugs faster than competitors and license its OS to other companies, building a network effect that improves its algorithm over time.
Cathie Wood's ARK Invest has been buying shares of Recursion Pharmaceuticals, a biotech company using AI to speed up drug discovery. It is now the third-largest holding in her ARK Genomic Revolution ETF. Recursion has developed an AI-powered operating system that conducts up to 2.2 million weekly experiments to test drug candidates in an automated laboratory, advancing only the most promising compounds to clinical trials. Using AI this way could allow Recursion to launch drugs faster than competitors and license its OS to other companies, building a network effect that improves its algorithm over time.
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_nacon-revolution-unlimited-pro-review-weird-quirks-and-features.webp "Gamer Heaven")
_renault-symbioz-interior-design-in-iconic-bleu-mercure.webp "A true ‘voiture à vivre’, Renault 16 was designed to stand apart from the competition. Launched in 1965, it premiered a new body style, with hatchback access to the boot. More versatile than any of its contemporaries, Renault 16 included a bench seat adjustable for a 'holiday travel' position. It met the needs of families looking for a car that suited their lifestyles, while keeping pace with rapid social change.<br/><br/>Since then, Renault has continued to innovate with family cars that caught the mood of their times. This was true in the 1980s with Espace, a car that started a revolution with its groundbreaking one-box design and modular layout. In the 1990s, Renault did it again with Scénic, the first compact MPV. Designed to resemble a cocoon, Scénic featured an interior dedicated to passenger well-being.<br/><br/>Symbioz shares this same DNA. Able to adapt its boot and passenger compartment to family needs, with useful technologies delivering human added value and compact dimensions that are also ideal for city driving, it joins a long line of versatile ‘voitures à vivre’, reflecting its times. Showcasing Renault's new design language, Symbioz follows on from the recent Scénic E-Tech electric and New Captur.")
_pioneer-dj-opus-quad-eva-molded-soft-case-with-wheels-bmpiopusquad.webp "Odyssey Innovative Designs")
_nacon-revolution-x-pro-controller-xbox-series-x-amp-pc.webp "WhatGear")
_bye-bye-ps5-dualsense-edge-this-is-the-nacon-revolution-5-pro.webp "Mirror Gaming")
_revolution-5-pro-controller-review-a-highly-unique-option-in-the-device-space-but-at-what-cost.webp "Noisy Pixel")
⏲ 19 minutes 7 seconds 👁 5.7K
_cathie-wood39s-ark-invest39s-third-largest-holding-is-this-little-known-biotech-company-harnessing-ai-for-drug-treatment.webp "Cathie Wood's ARK Invest has been buying shares of Recursion Pharmaceuticals, a biotech company using AI to speed up drug discovery. It is now the third-largest holding in her ARK Genomic Revolution ETF. Recursion has developed an AI-powered operating system that conducts up to 2.2 million weekly experiments to test drug candidates in an automated laboratory, advancing only the most promising compounds to clinical trials. Using AI this way could allow Recursion to launch drugs faster than competitors and license its OS to other companies, building a network effect that improves its algorithm over time.")
_aliens-are-here-and-they39re-not-our-friends-john-lear-says-part-1.webp "8 News Now — Las Vegas")
_nacon-revolution-unlimited-pro-review-weird-quirks-and-features.jpg)
_renault-symbioz-interior-design-in-iconic-bleu-mercure.jpg)
_pioneer-dj-opus-quad-eva-molded-soft-case-with-wheels-bmpiopusquad.jpg)
_nacon-revolution-x-pro-controller-xbox-series-x-amp-pc.jpg)
_bye-bye-ps5-dualsense-edge-this-is-the-nacon-revolution-5-pro.jpg)
_revolution-5-pro-controller-review-a-highly-unique-option-in-the-device-space-but-at-what-cost.jpg)
_aliens-are-here-and-they39re-not-our-friends-john-lear-says-part-1.jpg)
![[+]](/images/menu.gif){kind=small}